Search Results

Mesoblast Limited, Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, confirmed that it will file its Biologics License Application for approval of Ryoncil® in the treatment of children with steroid-refractory acute graft versus host disease with the U.S. Food and Drug Administration next week.

Mesoblast Limited announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.

Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).